<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973710</url>
  </required_header>
  <id_info>
    <org_study_id>ProHealth-2</org_study_id>
    <nct_id>NCT03973710</nct_id>
  </id_info>
  <brief_title>Effect of Probiotics on Blood Pressure Management</brief_title>
  <official_title>Role of Probiotics in the Prevention of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dysbiosis of gut microbiota has been reported to be involved in the development and
      progression of hypertension in both humans and animal models. Probiotics have been reported
      to have ameliorative effects in murine models. However, whether probiotics could help
      alleviate hypertension in adults remain obscure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probiotics are live microorganisms that have been associated with multiple health benefits.
      However, its protective role in adults has long been controversial. This study aims to
      examine the effect of 12-week probiotics supplementation on the prevention of hypertension in
      Chinese adults. By understanding the mechanisms by which probiotics exert this beneficial
      effects, we can better control the rising prevalence of hypertension, which is a major risk
      factor for cardiovascular diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, investigators and care providers at the scene are all blinded to the allocation of treatment group. Data collected will be analyzed by another investigator who is blinded to the study design.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>changes of systolic blood pressure</measure>
    <time_frame>baseline, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>changes of systolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of diastolic blood pressure</measure>
    <time_frame>baseline, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>changes of diastolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of gut microbiota</measure>
    <time_frame>baseline, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>changes of gut microbiota by metagenomics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of pulse wave velocity</measure>
    <time_frame>baseline and after 12-week intervention</time_frame>
    <description>changes of pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of ankle brachial index</measure>
    <time_frame>baseline and after 12-week intervention</time_frame>
    <description>changes of ankle brachial index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of microbial metabolite</measure>
    <time_frame>baseline and after 12-week intervention</time_frame>
    <description>changes of microbial metabolite by untargeted metabolomics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Probiotics group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus paracasei dietary supplement</intervention_name>
    <description>a commercial probiotic dietary supplement</description>
    <arm_group_label>Probiotics group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo controls</intervention_name>
    <description>placebo with a similar appearance to probiotics supplement</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible subjects include men and women 18 to 75 years of age with pre-hypertension
             who has a systemic blood between 120 and 139 mmHg and/ or a diastolic blood pressure
             between 80 and 80 mmHg;

          -  Absence of any diet, dietary supplement and medications that might interfere with
             blood pressure and gut microbiota, especially antibiotics and probiotics.

        Exclusion Criteria:

          -  Any other systemic, metabolic and cardiovascular or cerebrovascular diseases;

          -  Type 1 diabetes, type 2 diabetes treated with insulin or other medications;

          -  Acute illness or current evidence of acute or chronic inflammatory or infective
             diseases;

          -  Participation in any diet or lifestyle program more than 2 times per week in the
             latest 3 months prior to recruitment;

          -  Mental illness rendering them unable to understand the nature, scope, and possible
             consequences of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Xia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Xia, PhD</last_name>
    <phone>+86 20 87332433</phone>
    <email>xiamin@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiyun Luo, MBBS</last_name>
    <phone>+86 189 2786 5282</phone>
    <email>297244456@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nutrition and Food Hygiene</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Xia, PhD</last_name>
      <phone>+86 20 87332433</phone>
      <email>xiamin@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Min Xia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Prevention</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

